Two years after the start of the COVID pandemic that disrupted not only our lives, but also our way of working, we have learned to juggle, more or less effectively, a thousand new challenges and opportunities for change.
Two years after the start of the COVID pandemic that disrupted not only our lives, but also our way of working, we have learned to juggle, more or less effectively, a thousand new challenges and opportunities for change.
Our goal is not the mere transposition of paper documentation to a digital medium, but the redesign of the quality process enabled by digital technology to make it more efficient, faster, visible, accessible and in compliance with the Data Integrity requirements of the pharmaceutical sector.
Life Science: Once upon a time, there was a paper-based procedure
The transformation of procedures from paper to knowledge: this was the theme of the webinar organised by LifeBee last March 3, with the patronage of Assolombarda and the original and innovative contribution of Heike Roeder
Qualified Person and Digitalization
NCF Notiziario Chimico Farmaceutico - Nr 5, June 2020 - by Mirka Broccato The Covid-19 tsunami has further confirmed to what degree Digitalization plays a central role in enabling remote working in total compliance if conditions should require. The role of the Qualified Person (QP) is to ensure the quality of a medicine, employing the […]
Digital Therapies: when the Medicine is Software
Teresa Minero for ICF – Rivista dell’Industria Chimica e Farmaceutica – May 2020 The Digital Therapeutics Alliance (DTA) defines Digital Therapies (or DTx) as follows: "They offer scientifically supported, therapeutic interventions to patients, who are then monitored by high-quality software programs to prevent, manage or treat a broad spectrum of behavioural, physical and mental conditions." […]
Pharma 4.0: a new perspective of opportunities and constraints
Teresa Minero, Founder & CEO LifeBee e Alberto Augeri, Managing Consultant LifeBee, firmano l’articolo “Pharma 4.0: a new perspective of opportunities and constraints” per MEDIC Volume 26 – Dicembre 2018 – Pacini Editore Medicina. Industry 4.0: the concept is not new, yet 4.0 opens a brand-new perspective: everybody is involved, with new technologies. Pharma 4.0 […]
The Covid-19 health emergency has confirmed that a digital company is also a resilient company, capable of adapting quickly in the wake of unforeseen events and guaranteeing effectiveness and continuity of its core business processes.
In our DNA is the drive to approach MES management in Pharma with an overview that simultaneously addresses all the compliance, data integrity, efficiency and impact requirements that the final solution will need to meet.
On 23 November, during the ISPE 2020 Annual Virtual European Meeting & Expo, a roundtable discussion was held with participants from several major international regulatory authorities on the topic of Distant Assessments During and After COVID-19.
In association with
In support of:
